Albert Diaz-Ordaz, MD
Gastroenterology · Orchard Park, NYNPI 1588735203
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 314 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 43.2% of the total.
Across 314 payments — averaging $20.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Pfizer$879
- Phathom Pharmaceuticals, Inc.$668
- Takeda Pharmaceuticals U.S.A., Inc.$407
- Pentax Of America, Inc.$355
- Regeneron Healthcare Solutions, Inc.$353
- plus $972 from 9 others
Across 110 payments — averaging $1249.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shire North American Group Inc$52K
- Takeda Pharmaceuticals U.S.A., Inc.$37K
- Bristol Myers Squibb$27K
- Genentech, Inc.$22K
What the payments were for
- Food & beverage$6,392100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 74 | $2,766 |
| Pfizer | 56 | $879 |
| Phathom Pharmaceuticals, Inc. | 80 | $668 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $407 |
| Pentax Of America, Inc. | 11 | $355 |
| Regeneron Healthcare Solutions, Inc. | 9 | $353 |
| Johnson & Johnson | 41 | $338 |
| Sanofi | 8 | $223 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $96 |
| Fujifilm Healthcare Americas Corporation | 4 | $85 |
| Bristol Myers Squibb | 5 | $79 |
| Braintree Laboratories, Inc. | 2 | $44 |
| Boston Scientific | 1 | $43 |
| Novo Nordisk | 2 | $43 |
| Ferring Pharmaceuticals Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,400 in reported general payments places this provider in the 70th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Famotidine | 127 | $1,247 |
| Pantoprazole Sodium | 54 | $500 |
| Clotrimazole | 18 | $453 |
| Esomeprazole Magnesium | 12 | $322 |
| Rabeprazole Sodium | 18 | $308 |
| Omeprazole | 33 | $233 |
| Nadolol | 16 | $151 |
| Lansoprazole | 11 | $99 |
| Ondansetron Hcl | 14 | $21 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Orchard Park
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Maya SrivastavaWilliamsville$1.8M
- Melissa PalmerPlainview$1M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
- Bruce SandsNew York$810K
- Jean Frederick ColombelNew York$786K
- Seth GrossNew York$624K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.